| Literature DB >> 27617489 |
Su Ryon Shin1,2,3, Yu Shrike Zhang1,2,3, Duck-Jin Kim1,2, Ahmad Manbohi1,2,4, Huseyin Avci1,2,5, Antonia Silvestri1,2,6, Julio Aleman1,2, Ning Hu1,2,7, Tugba Kilic1,2,8, Wendy Keung9,10, Martina Righi1,2,11, Pribpandao Assawes1,2, Hani A Alhadrami12,13, Ronald A Li9,10, Mehmet R Dokmeci1,2,3, Ali Khademhosseini1,2,3,14,15.
Abstract
Continual monitoring of secreted biomarkers from organ-on-a-chip models is desired to understand their responses to drug exposure in a noninvasive manner. To achieve this goal, analytical methods capable of monitoring trace amounts of secreted biomarkers are of particular interest. However, a majority of existing biosensing techniques suffer from limited sensitivity, selectivity, stability, and require large working volumes, especially when cell culture medium is involved, which usually contains a plethora of nonspecific binding proteins and interfering compounds. Hence, novel analytical platforms are needed to provide noninvasive, accurate information on the status of organoids at low working volumes. Here, we report a novel microfluidic aptamer-based electrochemical biosensing platform for monitoring damage to cardiac organoids. The system is scalable, low-cost, and compatible with microfluidic platforms easing its integration with microfluidic bioreactors. To create the creatine kinase (CK)-MB biosensor, the microelectrode was functionalized with aptamers that are specific to CK-MB biomarker secreted from a damaged cardiac tissue. Compared to antibody-based sensors, the proposed aptamer-based system was highly sensitive, selective, and stable. The performance of the sensors was assessed using a heart-on-a-chip system constructed from human embryonic stem cell-derived cardiomyocytes following exposure to a cardiotoxic drug, doxorubicin. The aptamer-based biosensor was capable of measuring trace amounts of CK-MB secreted by the cardiac organoids upon drug treatments in a dose-dependent manner, which was in agreement with the beating behavior and cell viability analyses. We believe that, our microfluidic electrochemical biosensor using aptamer-based capture mechanism will find widespread applications in integration with organ-on-a-chip platforms for in situ detection of biomarkers at low abundance and high sensitivity.Entities:
Year: 2016 PMID: 27617489 PMCID: PMC5844853 DOI: 10.1021/acs.analchem.6b02028
Source DB: PubMed Journal: Anal Chem ISSN: 0003-2700 Impact factor: 6.986